In this podcast we talk to Kuldeep Singh Rajput, founder and CEO of Biofourmis. HealthXL and Kuldeep go way back! In fact, we first learned about a great entrepreneur based out of Singapore 5 years ago, well before anybody knew what a stellar takeoff Kuldeep would embark on.

‍

In 2015, mid-way through a doctoral programme, Kuldeep took the bold decision to ditch his PhD and embark on a mission to transform the healthcare industry. Kuldeep gives us a whistle-stop tour of his journey which took him from India, to MIT Media Lab and ultimately to Singapore where he founded Biofourmis. While his company could have taken any direction, it was the decision to focus on the unmet needs of heart failure patients that shaped Biofourmis’ therapeutic pipeline and, ultimately, its value proposition. (Did you know that in the US less than 1% of heart failure patients receive optimal dosage and that less than 20% are on guideline directed therapy?)  Kuldeep also tells us about Biofourmis’ partnership with the FDA, its approach to business and navigating the complexity of the US health market.

‍

Podcast #9: Kuldeep Singh Rajput

‍

Available on Spotify, iTunes, and Castbox

‍

Asked what he would do if we hadn’t founded Biofourmis, Kuldeep tells us that he likely would have followed in his parents’ academic footsteps and finished his PhD, though eventually, he would have become an entrepreneur anyway.

‍

We recorded this podcast pre-Covid, in September of last year to be specific, when Kuldeep visited Dublin to speak at our Global Gathering. Biofourmis has since partnered with Novartis, acquired Biovotion and launched a national Covid-19 disease surveillance programme in Hong Kong (in partnership with The University of Hong Kong and Hong Kong’s Department of Health).